| NAME | SYMBOL | EXCHANGE |
| Alpha RX Inc. | ALRX | PinkSheets / OTCBB |
| SHARES OUTSTANDING | FINANCIALS | INDUSTRY |
| 92,371,192 A/O 2010/2/11 | View Filings | Pharmaceutical / Drugs |
| TRANSFER AGENT | BROKER FACT SHEET | WEBSITE |
| Signature Stock Transfer, Inc. | Fact Sheet | www.AlphaRX.com |
Hong Kong, March 16 – AlphaRx Inc. (OTC BB:ALRX), today provided an update on its internal product candidates and development plans. Highlights of the Company’s product review and upcoming corporate milestones include: * Over the last 12 months we have made significant progress in moving ARX8203 toward...
[Continue reading: AlphaRx Provides Corporate and Development Update]Hong Kong, May 10, 2010 (MARKETWIRE) — AlphaRx, Inc. (OTCBB: ALRX), has been advised by Cypress Biosciences (“Cypress”), its development partner for Indaflex, that Cypress is not funding development of Indaflex. Notwithstanding the termination of all Indaflex activity in the U.S.A., AlphaRx continues...
[Continue reading: AlphaRx Provides Update on Indaflex]Companies need to periodically consider actions that unlock their intrinsic value. At this point in time, AlphaRx is pursuing such an opportunity. Hong Kong, March 29, 2010 (MARKETWIRE) — AlphaRx, Inc. (OTCBB: ALRX) today announced that the Company plans to list its’ Canadian subsidiary, which has been focused...
[Continue reading: AlphaRx Plans to List Subsidiary]
